2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

Abecma was filed for approval on the back of the KarMMA-3 study in patients who had failed two to four lines of prior therapy, which showed the treatment cut the risk of disease progression or ...

Explore the investment prospects of 2seventy Bio, a spin-off from bluebird bio, in the competitive field of cell therapies ...

Abecma. The study named KarMMa-9 targeted patients with newly diagnosed multiple myeloma (NDMM), a type of bone marrow cancer, who have had an inadequate response to autologous stem cell transplant.

This revenue growth is complemented by a strategic decision to discontinue the KarMMa-9 study ... breakeven operations by continuing to expand Abecma’s market presence while streamlining ...

"Our data on Breyanzi and Abecma at ASH reaffirm how our approved CAR T cell therapies continue to demonstrate favorable long-term outcomes, while results from our pipeline offer potential to ...

Idecabtagene vicleucel (ide-cel; Abecma), meanwhile ... The third-line approval of ide-cel was based on findings from the KarMMa-3 trial, which included 386 patients randomized 2:1 to either ...